Probabilities of being the best among competing antidepressant agents when reporting bias affects one specific agent.

<p>The first stacked bar at the left corresponds to the network meta-analysis free of reporting biases (ie, with the data from the 74 FDA-registered trials). The other stacked bars correspond to the 12 network meta-analyses in which reporting bias hypothetically affects one specific agent in turn. For instance, for mirtazapine, we used the 6 published trials (out of 10 FDA-registered trials), with published effect sizes, and data from the 64 FDA-registered trials for the other 11 agents, which resulted in an incomplete FDA network of 70 trials; the probability of mirtazapine being the best was 80.6% with data from the incomplete FDA network and 7.3% with data from the 74 FDA-registered trials. For the sake of clarity, we presented in each analysis the 3 drugs with the 3 highest probabilities of being the best among competing antidepressant agents. Bup: Bupropion; Cit: Citalopram; Dul : Duloxetine ; Esc: Escitalopram; Flu: Fluoxetine; Mir: Mirtazapine ; Nef: Nefazodone ; Par: Paroxetine; Par CR: Paroxetine CR; Ser: Sertraline; Ven: Venlafaxine; VenXR: Venlafaxine XR.